Customers will present data from their use of novel assays
and kits; company will host educational workshops and discussions
for attendees
MINNEAPOLIS, Nov. 14,
2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:
TECH) today announced its lineup of presentations and activities
for the Association for Molecular Pathology (AMP) 2024 Annual
Meeting & Expo, taking place November
19-23 in Vancouver, British
Columbia. Asuragen, a Bio-Techne brand, will be exhibiting
and showcasing its latest research products for breast cancer
monitoring and carrier screening in booth #811.
"The Association for Molecular Pathology is a leading voice in
the world of clinical molecular testing. We look forward to its
meeting every year to discuss the latest advances in molecular
diagnostics and how they can be deployed for improved laboratory
outcomes," said Dr. Matt McManus,
President of Bio-Techne's Diagnostics & Spatial Biology
Segment. "This year, we're excited to highlight important new
products that will help labs streamline data collection and
analysis in critical areas including metastatic breast cancer and
carrier screening."
At the AMP 2024 Annual Meeting & Expo, Asuragen will host,
sponsor, or participate in a number of activities and
presentations.
ESR1 & Beyond: Leveraging Exosomes for
Highly-Sensitive Variant Detection on qPCR
This workshop
will showcase the design and performance of the
QuantideX® qPCR ESR1 exoMutation Kit combined
with the ExoLution Plus cfDNA + exoRNA Isolation Kit to achieve
analytical sensitivity of ≤0.1% across 11 ESR1
mutations, utilizing the power of cfDNA and exosomal RNA to deliver
best-in-class performance using commonly-available qPCR
instruments.
Speaker: Brian Haynes,
PhD, Bio-Techne Diagnostics Division
Date and
time: Wednesday, November 20,
3:00-3:50 PM PST
Location:
Room 212/213
Long-Range PCR Meets Long-Read Sequencing: An Assay for 11
Hard-to-Decipher, High-Frequency Carrier Screening Associated
Genes
This workshop will focus on the design and performance
of the AmplideX® Nanopore Carrier Plus Kit, combining
AmplideX PCR chemistry with the Oxford Nanopore®
platform to identify the most challenging genetic alterations like
CNVs, large inversions, and pseudogenes using a consolidated
workflow.
Speaker: Paul A. Wadsworth,
MD, PhD, Resident Physician, Pathology, Stanford University
Date and time:
Wednesday, November 20, 12:00-12:50 PM PST
Location: Room
114/115
Fireside Chat: LDT Compliance in an Uncertain
Environment
With so much uncertainty around the FDA's
laboratory-developed test (LDT) rule, it is challenging for
laboratory leaders to make firm plans for how to achieve
compliance. This session will consider three different tactical
approaches for stage I of the rule: a) labs actively preparing for
compliance; b) labs preparing, but cautiously using resources; and
c) labs that are taking a 'wait and see' approach.
Discussion Leader: Jordan
Laser, MD, Asuragen
Date and time: Wednesday, November 20, 5:15-6:15 PM PST
Location: Room
211
POSTERS
Verification of an RT-qPCR Assay System for Liquid Biopsy
Surveillance of Treatment-Resistant ESR1 Mutations
Presenting author: Blaine
Caughron, Asuragen
Poster info: G095, Genetics;
Saturday, November 23, 9:15 am -10:15 am
Verification of an Amplification-Based Nanopore Sequencing Assay
and Software to Genotype Complex, Clinically-Relevant Variants in
11 Hard-to-Decipher Genes with High Carrier Frequencies
Presenting author: Connor A.
Parker, Asuragen
Poster info: G094, Genetics;
Friday, November 22, 9:15 am -10:15 am
Freeze-Dried, Worry Thawed: Armored RNA New Lyophilized Controls
Offer Potential to Advance Molecular Testing in Resource Limited
Settings
Presenting author: Deepa
Eveleigh, Asuragen
Poster info: ID046, Infectious
Disease; Friday, November 22,
9:15 am -10:15 am
Beta Evaluation of a Panel of 11 Challenging Genes Using
ONT/AmplideX Chemistry
Presenting author: Anne-Sophie
Lebre, Professor of Human Genetics & Clinical Molecular
Geneticist, Reims Medical School & University
Hospital
Poster info: G013, Genetics; Saturday, November 23, 9:15am -10:15am
Stop by the Asuragen booth (#811) to learn more about the
company's products for clinical laboratories. We will also be
providing free, professional-quality headshots to all AMP attendees
who visit our booth on Thursday or Friday.
For more information about Asuragen's AMP 2024 activities,
please visit
https://www.bio-techne.com/about/events/association-molecular-pathology.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences
company providing innovative tools and bioactive reagents for the
research and clinical diagnostic communities. Bio-Techne products
assist scientific investigations into biological processes and the
nature and progress of specific diseases. They aid in drug
discovery efforts and provide the means for accurate clinical tests
and diagnoses. With hundreds of thousands of products in its
portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has
over 3,100 employees worldwide. For more information on Bio-Techne
and its brands, please visit https://www.bio-techne.com or follow
the Company on social media at: Facebook, LinkedIn, Twitter or
YouTube.
Contact:
David Clair,
Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-highlight-novel-solutions-for-cancer-and-carrier-screening-at-amp-2024-annual-meeting--expo-302305212.html
SOURCE Bio-Techne Corporation
